.tb-field[data-toolset-blocks-field="89a01bfaf85a0b73fc3cb3a1aef30971"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="2c985e5b0c690adec81b41c2ec06af4a"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="c35d9a7279448f10d949ebc7e457ae45"] { text-align: left;justify-content: flex-start; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { background-color: rgba( 217, 217, 217, 0.13 );padding: 10px;margin-bottom: 15px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 215, 213, 213, 1 );grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-field[data-toolset-blocks-field="627e912eb953c8ed786ea0c7e10207ea"] { font-size: 14px;text-align: left;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }   h1.tb-heading[data-toolset-blocks-heading="4273ccf7ca31e5697065fdb41a036bd2"]  { font-size: 26px; }  .wpv-custom-search-filter-submit[data-toolset-views-custom-search-submit="8ca7a9b3f80df5aa18fe74ad2a58d731"] { text-align: left; } @media only screen and (max-width: 781px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } @media only screen and (max-width: 599px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } 

News and Press Releases

Emmes Coordinates Groundbreaking Stem-Cell Ophthalmology Trial

18 February 2026 -- Maryland, US -- Emmes, a full-service, global Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation – in collaboration with the UC Davis Eye...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 18, 2026

Emmes

401 North Washington Street Suite 700 Rockville, MD 20850

Levicept Announces the Appointment of James Sandy as Chief Development Officer

Leadership Team Strengthened to Support Clinical Development of LEVI-04 for Osteoarthritis 4 February 2026 -- Sandwich, UK -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: February 4, 2026

Levicept

info@levicept.com

Innovation House Discovery Park Ramsgate Road Sandwich Kent CT13 9ND

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Series A led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments 8 October 2025 -- New York, New York...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025

Nilo Therapeutics

info@nilotx.com

Oxeltis and academic partners receive grant funding worth nearly €800,000 to develop antiviral for Bunyaviricetes

France’s National Research Agency (ANR) and Defense Innovation Agency (AID) will finance BUNYANTIVIR project to introduce novel therapeutic approach for Bunyaviricetes class of human pathogenic viruses found in tropical and...

Category:
Posted: June 25, 2025

Oxeltis

Cap Gamma, 1682 rue de la Valsière, BP 7247 34086 Montpellier Cedex 4 – France

Advarra Integrates Study Startup and IRB Technologies, Enabling Unprecedented Visibility into Clinical Trial Site Activation

New release of Advarra’s Study Collaboration solution provides sponsors and CROs a single view into the progress of site activation milestones and IRB review status across sites 17 April 2025...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2025

Advarra

6100 Merriweather Dr., Suite 600 Columbia, MD 21044

Pistoia Alliance Launches Initiative to Assess Sustainability of Digital vs. Traditional Clinical Trial Approaches

New initiative will collect pharma and CRO data to refine industry carbon measurement of technologies like remote monitoring and eConsent, informing more sustainable trial design 20 March 2025, Massachusetts, US...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

The Pistoia Alliance

info@pistoiaalliance.org

401 Edgewater Pl, Wakefield, Massachusetts, US

Innovaderm Research Rebrands as Indero, a dual-focus CRO

7 March 2025 -- Quebec, Canada -- Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025

Indero

3530 Saint-Laurent boulevard, Suite 300 Montreal, QC, H2X 2V1, Canada

Schrödinger Selects Sapio Sciences to Enhance In Silico Drug Discovery From Plasmid to Structure

Configurable informatics platform improves lab efficiency, data tracking, and resource management from plasmid to structure 28 January 2025 – Baltimore, MD, US – Sapio Sciences, the science-aware™ lab informatics platform,...

Category: BioManufacturing, Drug Discovery
Posted: January 28, 2025

Sapio Sciences

400 East Pratt Street #800 Baltimore, MD 21202

ACG to Showcase Sustainable Packaging Innovations at Pharmapack Paris 2025

Welcomes Jochen Scheil as Head of Global Sales for ACG Packaging Materials 21 January 2025 -- Paris, France -- ACG, the world’s leading supplier of integrated solutions for the pharmaceutical...

Category: Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: January 21, 2025

ACG World

D Bhabrekar Nagar Road Mumbai, Maharashtra 400067, IN

Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials

9 January 2025 -- Cambridge, UK and Montreal, Canada -- Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 9, 2025

Biofidelity

5151 McCrimmon Parkway, Suite 230 Morrisville, NC 27560

DeanHouston Appoints New Director of Hygienic Markets

Jeff Blease brings more than 31 years of industry experience 8 January 2025 -- Kentucky, US -- DeanHouston, a business-first marketing firm that excels at creating meaningful communication strategies for...

Category: Other
Posted: January 8, 2025

DeanHouston

cincinnati@deanhouston.com

525 Scott Street Suite 201 Covington, KY 41011

Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors

Mr. Satter’s Extensive Investment, Company-Building, and Transaction Experience Strengthens Alzheon’s Board Leadership Valiltramiprosate/ALZ-801 Has Potential to Become the First Oral Agent to Slow Alzheimer’s Pathology in Patients APOLLOE4 Pivotal Phase...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 7, 2025

Alzheon

111 Speen Street, Suite 306 Framingham, MA 01701

IDDI Announces New Leadership to Drive Growth and Innovation

Tim Davis appointed as new Chief Executive Officer and Jeremy Edwards named the new Chief Commercial Officer 7 January 2025 -- Ottignies, Belgium -- International Drug Development Institute (IDDI), a...

Category: Clinical Trials, Other, Pharmaceutical
Posted: January 7, 2025

IDDI

info@iddi.com

Avenue Provinciale, 30 1341 Ottignies-Louvain-la-Neuve Belgium

CluePoints Appoints Richard Young as Chief Strategy Officer

28 October 2024 -- Pennsylvania, US -- RBQM innovator CluePoints has today announced that Richard Young has been appointed as its new Chief Strategy Officer. With 30 years of experience...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 28, 2024

CluePoints

contact@cluepoints.com

1000 Continental Drive, Suite 240, King of Prussia, PA 19406

Coronado Research Limited announce appointment of Professor Jennifer Visser-Rogers as Chief Scientific Officer

24 October 2024 -- London, UK -- Coronado Research announced today that Professor Jennifer Visser-Rogers has been appointed as Chief Scientific Officer. Jennifer brings with her a broad portfolio of...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: October 24, 2024